We sought to identify and summarize the incidence and prevalence of neuropathy among HIV patients and subgroups. A systematic search of the literature was performed using MEDLINE and EMBASE. The relevant literature was identified based on predefined criteria. Prevalence data were collected from cross-sectional and cohort studies. Incidence data were collected from cohort and case-control studies. Thirty-seven studies were included of which there were 23 cohort studies, 13 cross-sectional studies, and one case-control study. The prevalence of neuropathy among HIV patients derived from 25 studies varied from 1.2% to 69.4%. Regarding the development of neuropathy among HIV-positive patients, standardized by study duration, the rates per 100 person-years ranged from 0.7 to 39.7. Among older patients there is a greater risk of neuropathy. The same seems to be the case for patients with more severe disease. Currently available studies providing information on the incidence and prevalence of neuropathy among HIV patients suggest a significant burden, but there is a great variation in results across studies. There is no definitive explanation for the variation. However, it underscores the fact that complexity of the disease, along with absence of standardized diagnostic criteria, has considerably influenced the methodologies and outcomes of the studies.
Get full access to this article
View all access options for this article.
References
1.
UNAIDS/WHO: 2008 Report on the Global AIDS Epidemic; 2008Online2010.
2.
RatnamKV, TanCK. A review of neurological complications in AIDS. Singapore Med J, 1989; 30,2:199–201.
3.
PortegiesP, SolodL, CinqueP, ChaudhuriA, BegovacJ, EverallIet al.Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol, 2004; 11,5:297–304.
CDC: 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and AdultsOnline2010611, 2010.
6.
HerrmannDN, McDermottMP, SowdenJE, HendersonD, MessingS, CruttendenKet al.Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology, 2006; 66,6:857–861.
7.
PardoCA, McArthurJC, GriffinJW. HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst, 2001; 6,1:21–27.
BergerA, DukesEM, OsterG. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain, 2004; 5,3:143–149.
15.
CherryCL, WesselinghSL, LalL, McArthurJC. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology, 2005; 65,11:1778–1781.
16.
EnglandJD, GronsethGS, FranklinG, CarterGT, KinsellaLJ, CohenJAet al.Practice parameter: Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology, 2009; 72,2:177–184.
SchifittoG, McDermottMP, McArthurJC, MarderK, SacktorN, McClernonDRet al.Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology, 2005; 64,5:842–848.
19.
DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsOnline2010.
20.
YeniPG, HammerSM, HirschMS, SaagMS, SchechterM, CarpenterCCet al.Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA, 2004; 292,2:251–265.
21.
CherryCL, AffandiJS, ImranD, YunihastutiE, SmythK, VanarSet al.Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology, 2009; 73,4:315–320.
22.
BacellarH, MunozA, MillerEN, CohenBA, BesleyD, SelnesOAet al.Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology, 1994; 44,10:1892–1900.
23.
ShethSG, RaoCV, TselisA, LewisRA. HIV-related peripheral neuropathy and glucose dysmetabolism: Study of a public dataset. Neuroepidemiology, 2007; 29,1–2:121–124.
24.
VillaA, ForestiV, ConfalonieriF. Autonomic nervous system dysfunction associated with HIV infection in intravenous heroin users. AIDS, 1992; 6,1:85–89.
25.
U.S. Department of Health and Human Services: Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug TreatmentOnline1991.
26.
Villelabeitia-JaureguizarK, Rivas-GonzalezP, Ibarra-LuzarJI, Fernandez-GarciaC, Goyenechea-HerreroA, Frenadas Bravo-RuedaAet al.[Clinical and subclinical neuropathy in patients with human immunodeficiency virus receiving antiretroviral therapy]Rev Neurol, 2006; 42,9:513–520.
27.
BarohnRJ, GronsethGS, LeForceBR, McVeyAL, McGuireSA, ButzinCAet al.Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol, 1993; 50,2:167–171.
28.
HallCD, SnyderCR, MessenheimerJA, WilkinsJW, RobertsonWT, WhaleyRAet al.Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction. Arch Neurol, 1991; 48,12:1273–1274.
29.
SoYT, HoltzmanDM, AbramsDI, OlneyRK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol, 1988; 45,9:945–948.
30.
WinerJB, BangB, ClarkeJR, KnoxK, CookTJ, GompelsMet al.A study of neuropathy in HIV infection. Q J Med, 1992; 83,302:473–488.
31.
BuchaczK, BakerRK, MoormanAC, RichardsonJT, WoodKC, HolmbergSDet al.Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005. AIDS, 2008; 22,11:1345–1354.
32.
CherryCL, SkolaskyRL, LalL, CreightonJ, HauerP, RamanSPet al.Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology, 2006; 66,6:867–873.
33.
CherryCL, RosenowA, AffandiJS, McArthurJC, WesselinghSL, PriceP. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res Hum Retroviruses, 2008; 24,2:117–123.
DragovicG, JevtovicD. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother, 2003; 14,5:281–284.
36.
IsezuoSA, SaniAZ, EzunuE, MaiyakiS, NjokuCH, ObembeA. Clinical neuropathy in HIV/AIDS: An eight-year review of hospitalized patients in Sokoto, northwestern Nigeria. Trop Doct, 2009; 39,3:133–135.
37.
LichtensteinKA, ArmonC, BaronA, MoormanAC, WoodKC, HolmbergSD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis, 2005; 40,1:148–157.
38.
LopezOL, BeckerJT, DewMA, CaldararoR. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur J Neurol, 2004; 11,2:97–102.
39.
MathewsWC, McCutchanJA, AschS, TurnerBJ, GiffordAL, KuromiyaKet al.National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care, 2000; 38,7:750–762.
40.
MooreRD, WongWM, KerulyJC, McArthurJC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS, 2000; 14,3:273–278.
41.
SilverbergMJ, GoreME, FrenchAL, GandhiM, GlesbyMJ, KovacsAet al.Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis, 2004; 39,5:717–724.
42.
SimpsonDM, KitchD, EvansSR, McArthurJC, AsmuthDM, CohenBet al.HIV neuropathy natural history cohort study: Assessment measures and risk factors. Neurology, 2006; 66,11:1679–1687.
43.
ZehenderG, ColasanteC, SantambrogioS, De MaddalenaC, MassettoB, CavalliBet al.Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr, 2002; 31,4:440–447.
44.
AffandiJS, PriceP, ImranD, YunihastutiE, DjauziS, CherryCL. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?AIDS Res Hum Retroviruses, 2008; 24,10:1281–1284.
45.
BeadlesWI, JahnA, WeigelR, ClutterbuckD. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop Doct, 2009; 39,2:78–80.
46.
GluckT, DegenhardtE, ScholmerichJ, LangB, GrossmannJ, StraubRH. Autonomic neuropathy in patients with HIV: Course, impact of disease stage, and medication. Clin Auton Res, 2000; 10,1:17–22.
47.
KarusD, RaveisVH, AlexanderC, HannaB, SelwynP, MarconiKet al.Patient reports of symptoms and their treatment at three palliative care projects servicing individuals with HIV/AIDS. J Pain Symptom Manage, 2005; 30,5:408–417.
48.
MorgelloS, EstanislaoL, SimpsonD, GeraciA, DiRoccoA, GeritsPet al.HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV Brain Bank. Arch Neurol, 2004; 61,4:546–551.
49.
NicholasPK, KemppainenJK, HolzemerWL, NokesKM, EllerLS, CorlessIBet al.Self-care management for neuropathy in HIV disease. AIDS Care, 2002; 14,6:763–771.
50.
ParryO, MielkeJ, LatifAS, RayS, LevyLF, SiziyaS. Peripheral neuropathy in individuals with HIV infection in Zimbabwe. Acta Neurol Scand, 1997; 96,4:218–222.
51.
PettersenJA, JonesG, WorthingtonC, KrentzHB, KepplerOT, HokeAet al.Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity. Ann Neurol, 2006; 59,5:816–824.
52.
SmythK, AffandiJS, McArthurJC, Bowtell-HarrisC, MijchAM, WatsonKet al.Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006. HIV Med, 2007; 8,6:367–373.
53.
SithinamsuwanP, PunthanamongkolS, ValcourV, OnsanitS, NidhinandanaS, ThitivichianlertSet al.Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr, 2008; 49,4:456–458.
54.
ZanettiC, ManzanoGM, GabbaiAA. The frequency of peripheral neuropathy in a group of HIV positive patients in Brazil. Arq Neuropsiquiatr, 2004; 62,2A:253–256.
55.
ZingmondDS, KilbourneAM, JusticeAC, WengerNS, Rodriguez-BarradasM, RabeneckLet al.Differences in symptom expression in older HIV-positive patients: The Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr, 2003; 33,Suppl 2:S84–S92.
56.
HulganT, HaasDW, HainesJL, RitchieMD, RobbinsGK, ShaferRWet al.Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS, 2005; 19,13:1341–1349.
57.
MoyleG. Toxicity of antiretroviral nucleoside and nucleotide analogues: Is mitochondrial toxicity the only mechanism?Drug Saf, 2000; 23,6:467–481.
58.
MoyleGJ, SadlerM. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Saf, 1998; 19,6:481–494.
59.
FichtenbaumCJ, CliffordDB, PowderlyWG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol, 1995; 10,2:169–174.
60.
DorseySG, MortonPG. HIV peripheral neuropathy: Pathophysiology and clinical implications. AACN Clin Issues, 2006; 17,1:30–36.
61.
CherryCL, AffandiJS, BrewBJet al.Ethnicity Is an Independent Predictor of Neuropathy Risk in HIV Patients. 18th conference on retroviruses and opportunistic infections, Boston, MA, February 2011.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
